Evidence map›Paper›PMID 15269710›Full record

ArticleGene therapy2004

Defining strategies to extend duration of gene expression from targeted compacted DNA vectors.

A-G Ziady, J Kim, J Colla, P B Davis

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Nanoparticles for retinal gene therapy.Progress in retinal and eye research · 2010
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

A-G ZiadyDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106-6006, USA.
J Kim
J Colla
P B Davis
University School · US

Funding

Translational Research in Cystic FibrosisP30DK027651 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI DRUMM, MITCHELL L · 1986 to 2014
$15.6M
CLEVELAND TRAINING PROGRAM IN CARDIOVASCULAR RESEARCHT32HL007653 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI DUBYAK, GEORGE R · 1988 to 2008
$3.5M
RESEARCH TRAINING PROGRAM PLANT32HL007415 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI DRUMM, MITCHELL L · 1985 to 2008
$2.8M
TARGETING THE SEC RECEPTOR FOR GENE THERAPYR01DK052981 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 1998 to 2001
$497k
NHLBI NIH HHS T32HL07415NHLBI NIH HHS T32 HL07653NIDDK NIH HHS P30 DK27651NIDDK NIH HHS R01 DK 52981
6 · The paper itself

Abstract

Gene transfer complexes containing poly-L-lysine (poly-K) and DNA with ligands directed at the serpin enzyme complex receptor (sec-R) deliver reporter genes to receptor-bearing cells in vivo. Expression lasts for about 30 days, when complexes containing long-chain poly-K are used. Extending the duration of expression would be desirable if correction of genetic defects is the goal. To test whether the mechanism by which expression is extinguished was due to an immune response to the transgene, or the loss of the transgene, we conducted two experiments. In the first, we injected sec-R-targeted lacZ complexes intravenously (i.v.) into mice genetically engineered to express this gene briefly during development. These mice, who should recognize the protein as 'self', also extinguished lacZ expression after 30 days. In a second experiment, we injected immunodeficient animals with sec-R-targeted human factor IX complexes. A similar temporal pattern of expression was observed in Rag-1 -/- mice, in whom expression also extinguished by 40 days. Moreover, factor IX plasmid DNA was detected in the lung and spleen 50 days after injection of complexes, suggesting that not all cells which had taken up the transgene had been destroyed. Thus, the host's immune response to the transgene may not account for the loss of reporter gene expression from these molecular conjugates. We further tested whether repeat administration of sec-R-targeted complexes will be limited by host immune responses. Mice were pre-dosed twice with sec-R-targeted complexes containing lacZ over a 40-day period. We then injected the animals i.v. with sec-R-targeted human factor IX complexes and measured gene expression and antibody production. Although 14 of 36 animals displayed low-titer antibodies to the ligand in targeted complex, expression levels were unaffected compared with virgin dosing. When the complexes were administered three times intranasally (n=10), no antibodies against the complex were detected in blood. Plasma from mice dosed with saline, nontargeted complex or naked DNA did not react with the ligand, ligand-poly K conjugate or targeted complex. All animals exhibiting human factor IX expression developed antibodies to that transgene by 21 days. Thus, at least three repeat administrations of sec-R-directed molecular conjugates are possible, provided that immune responses to the transgene itself are not limiting.

Indexed as

AnimalsAntibody FormationDNAFactor IXGene ExpressionGenetic TherapyInjections, IntravenousLac OperonMiceMice, Inbred C57BLMice, TransgenicReceptors, Cell SurfaceSerpinsTime FactorsDNAFactor IXReceptors, Cell Surfaceserpin-enzyme complex receptorSerpins

Identifiers

PMID15269710
OpenAlexW2081164402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.